Treatment	Cause	Edge Weight	Shared Publications
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 17: Eicosanoid Dysregulation and Cox Inhibition: Unveiling the Complex Links between COPD and Cardiovascular, Gastrointestinal, and Metabolic Disorders	0.1165644171779141	38
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 6: Intrauterine and Chronic Inflammation-Driven Dysregulation of Anti-Inflammatory Responses in COPD Development	0.1092436974789916	52
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 18: Unraveling the Molecular Interplay of β Adrenoceptors, Gasotransmitters, and Sulfonation in COPD Pathogenesis	0.10337972166998012	52
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 4: NLRP3 Inflammasome-Mediated Inflammatory Dysregulation in COPD Pathogenesis and Therapeutic Targets	0.053763440860215055	10
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 8: Estrogen-Regulated Autophagy and miRNA Networks in Endometriosis-Related COPD Pathogenesis	0.038535645472061654	20
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 16: Unveiling Novel Targets and Immune Mechanisms in COPD Pathogenesis: From Muscle Metabolism to Macrophage Polarization	0.03281027104136947	23
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 5: Environmental Toxicants and Cyclooxygenase Inhibition in Gastrointestinal COPD Pathways	0.03115264797507788	10
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 23: Hormetic Regulation of Oxidative Stress and Inflammatory Pathways in COPD and Related Ischemic Diseases	0.028169014084507043	18
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 37: Acute Lung Injury and Inflammatory Dysregulation as Precursors to COPD Progression and Exacerbation	0.028132992327365727	11
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 26: Epigenetic and Inflammatory Regulation of Oxidative Stress and Nitric Oxide Production in COPD Pathogenesis	0.024464831804281346	16
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 10: Natural Bioactive Polyphenols and Flavonoids as Potential Therapeutic Agents in COPD Prevention	0.01882845188284519	9
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 27: Neuroinflammatory Pathways in COPD Development: Shared Mechanisms with Neurodegenerative Conditions	0.017699115044247787	8
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 31: Cardiac Dysfunction and Inflammation: A Novel Link to COPD Pathogenesis and Comorbidity	0.01675977653631285	6
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 9: Joint Inflammation and Oxidative Stress as Contributing Factors to COPD Pathogenesis in Rheumatoid Arthritis Patients	0.01240694789081886	5
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 28: Inflammatory Pathways Linking Osteoarthritis and COPD: Shared Mechanisms of Cartilage Destruction and Matrix Degradation	0.011673151750972763	3
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 25: Wound Healing Dysregulation and Tissue Remodeling as Systemic Influencers of COPD Pathogenesis	0.010416666666666666	3
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 19: Adipose Tissue Inflammation and Metabolic Dysfunction in the Pathogenesis of COPD	0.00974025974025974	3
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 11: Gut-Respiratory Axis: Inflammatory Disorders and Immune Dysregulation in COPD Pathogenesis	0.00927643784786642	5
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 33: Gut Microbiota Dysbiosis and Intestinal Immune Homeostasis Disruption in COPD Pathogenesis	0.007389162561576354	3
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 22: Periodontal Disease as a Source of Systemic Inflammation and COPD Exacerbation	0.006329113924050633	1
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 7: Congenital and Interstitial Lung Diseases as Modifiers of Emphysema and Fibrosis in COPD	0.005988023952095809	3
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 15: Sleep-Related Pathophysiology and Environmental Exposures in COPD Etiology and Progression	0.005859375	3
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 38: Liver Damage, Inflammation, and Fibrogenesis as Systemic Consequences in COPD Pathogenesis	0.0056022408963585435	2
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 34: Skin Barrier Dysfunction and Inflammation as Potential Contributors to COPD Etiology and Progression	0.004705882352941176	2
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 12: Viral-Induced Hypercoagulability and Inflammatory Pathways to COPD Exacerbation and Tissue Damage	0.004464285714285714	2
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 35: Cardiovascular and Metabolic Comorbidities as Modifiable Risk Factors for COPD Exacerbation	0.004310344827586207	2
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 13: Hyperglycemia-Induced Oxidative Stress and Inflammation in Diabetic COPD Comorbidity	0.0037735849056603774	1
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 1: TNF Inhibition and Modulation of COPD Inflammatory Profiles in Complex Comorbidities	0.0033444816053511705	1
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 39: Renal Dysfunction and Inflammation as Critical Modulators of COPD Pathogenesis and Exacerbation Risk	0.003115264797507788	1
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 32: Autoimmune and Autoinflammatory Conditions as Indicators of COPD Risk and Disease Progression	0.003003003003003003	2
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 36: Elucidating the Complex Genetic and Epithelial Mechanisms Underlying COPD Susceptibility and Progression	0.0019550342130987292	2
COPD Treatment Cluster 30: Targeting Inflammatory Pathways with PPARγ Modulators and P2Y6 Antagonists for COPD Treatment	COPD Cause Cluster 21: Neuroinflammatory Pathways in COPD: Intersection of Systemic Inflammation and Neurological Dysfunction	0.001447178002894356	1
